We have obtained approval for a Phase I/II clinical trial of JS207 and JS212 for combined use
December 11, 2025
Source: drugdu
40
On December 10, TopAlliance Biosciences, in answering an investor question on an interactive platform, stated that the company has obtained approval for a Phase I/II clinical trial of combined use of JS207 (PD-1/VEGF bispecific antibody) and JS212 (EGFR/HER3 bispecific ADC), and plans to launch related clinical studies in the near future.
JS207 is currently in the Phase II clinical study stage. Combination explorations are underway in multiple tumor types, combining JS207 with various drugs such as chemotherapy, monoclonal antibodies, and ADCs. The company will actively explore a variety of combination regimens to maximize the synergistic effect of its pipeline.
It is noted that due to the early-stage research and development of pharmaceutical products and the lengthy, multi-stage cycle from R&D and clinical trial application to production, they are susceptible to various uncertainties.
https://finance.eastmoney.com/a/202512103587875995.html
By editor
Copyright©2025 Ddu. All rights reserved.
Read more on
- Multiple batches of quadrivalent influenza virus split vaccine have been sub-packaged and submitted for lot release approval; expected to be released to the market soon after approval December 12, 2025
- Ab&B Bio-Tech CO., LTD. JS Lyophilized Human Rabies Vaccine Initiates Phase III Clinical Trials December 12, 2025
- The ‘Sweetest’ HPV Vaccine Market is Gone | Haibin Interview December 12, 2025
- InnoCare Pharma announced that its first independently developed next-generation TRK inhibitor, zoletrazinib, has been approved for marketing in China December 12, 2025
- Is PD-1/VEGF dual antibody + ADC becoming the standard configuration? December 12, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
